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Figure 1.  Frequency of HCV RNA testing during study follow-up.  Total number of PWID in each year of study follow-up is given in 
brackets (excluding those who died during or prior to that year). 
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Table 1. Relative risk of receiving at least one HCV RNA test among PWID during study follow-up, where time at risk begins one year 
after completion of therapy and ends at earliest date of first RNA test, date of death or 31st December 2012. 
Factor Level PWID (%) Person 
Years 
No. of people 
who received ≥1 
RNA test during 
follow-up 
Total no. of 
RNA tests 
Estimated % tested 
by 3 years (95% CI) 
Univariate HR  
(95%CI) 
p Adjusted HR  
(95%CI) 
p 
Overall  448 910 277  413 59.9 (55.2-64.6)     
           
Gender 
 
Female 105 (23.5) 210 66  82 64.3 (54.7-73.9) 1.00 (Baseline)  1.00 (Baseline)  
Male 343 (76.5) 700 211  331 58.6 (53.3-64.0) 0.98 (0.74-1.29) 0.897 0.90 (0.65-1.24) 0.511 
           
Age* <35 139 (31.0) 248 94 146 65.9 (57.7-74.0) 1.00 (Baseline)  1.00 (Baseline)  
≥35 309 (69.0) 662 183  267 57.3 (41.7-63.0) 0.83 (0.65-1.07) 0.149 0.75 (0.56-1.01) 0.055 
           
Cirrhotic* No 416 (92.9) 877 251 359 58.4 (53.6-63.3) 1.00 (Baseline)  1.00 (Baseline)  
Yes 32 (7.1) 33 26 54 81.3 (63.3-93.9) 1.90 (1.27-2.85) 0.002 1.86 (1.15-3.00) 0.012 
           
Year initiated onto therapy 2000-2002 37 (8.3) 80 31 77 83.8 (70.4-93.4) 1.00 (Baseline)  1.00 (Baseline)  
 2003-2005 114 (25.4) 356 75 115 54.4 (45.6-63.7) 0.62 (0.41-0.95) 0.028 0.67 (0.43-1.03) 0.069 
 2006-2009 297 (66.3) 474 171 221 58.9 (53.1-64.8) 0.66 (0.45-0.97) 0.034 0.50 (0.33-0.76) 0.001 
           
Treatment experienced No 426 (95.1) 883 260 378 59.0 (54.3-63.9) 1.00 (Baseline)  1.00 (Baseline)  
Yes 22 (4.9) 27 17 35 76.7 (56.5-92.1) 1.66 (1.02-2.71) 0.043 1.53 (0.87-2.68) 0.135 
           
Opiate or Injection related 
hospital admission prior to 
being initiated onto therapy 
No 300 (67.0) 664 178 252 56.8 (51.1-62.6) 1.00 (Baseline)  1.00 (Baseline)  
Yes 148 (33.0) 246 99 161 66.0 (58.1-73.7) 1.31 (1.03-1.68) 0.030 1.28 (0.96-1.71) 0.097 
           
Opiate or Injection related 
hospital admission during 
follow-up 
No 403 (90.0) 803 248 344 59.4 (54.5-64.3) 1.00 (Baseline)  1.00 (Baseline)  
Yes 45 (10.0) 107 29 69 63.9 (49.6-77.9) 0.89 (0.61-1.31) 0.571 0.84 (0.54-1.29) 0.422 
*At start of Rx.  PWID=People who inject drugs, RNA=Ribonucleic acid, CI=confidence interval, HR=Hazard Ratio. 
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Table 2. Detection of HCV reinfection among PWID who have received at least one RNA test during study follow-up, where time at risk 
begins one year after completion of therapy and ends at earliest date of reinfection (midpoint between last negative RNA test and first 
positive RNA test), last negative RNA test (for PWID who are not reinfected) or date of death. 
Factor Level PWID  
(col %) 
Person 
Years 
No. of 
reinfections  
(col %) 
Reinfection 
rate/100 PY (95%CI) 
Univariate HR  
(95% CI) 
p AHR  
(95% CI) 
p 
Overall  277 410 7 1.71 (0.69-3.52)     
          
Gender Female 66 (23.8) 68 2 (28.6) 2.94 (0.36-10.62) Ref  Ref  
Male 211 (76.2) 342 5 (71.4) 1.46 (0.47-3.41) 0.66 (0.13-3.42) 0.619 0.78 (0.13-4.59) 0.783 
          
Age* <35 94 (33.9) 155 2 (28.6) 1.29 (0.16-4.66) Ref  Ref  
≥35 183 (66.1) 255 5 (71.4) 1.96 (0.64-4.58) 1.40 (0.27-7.24) 0.686 1.92 (0.32-11.42) 0.471 
          
Cirrhotic* No 251 (90.6) 348 7 (100.0) 2.01 (0.81-4.14)     
Yes 26 (9.4) 62 0 (0) 0     
          
Year initiated onto therapy 2000-2002 31 (11.2) 103 1 (14.3) 0.97 (0.02-5.41) Ref  Ref  
 2003-2005 75 (27.1) 153 2 (28.6) 1.31 (1.58-4.72) 1.08 (0.10-11.91) 0.952 1.33 (0.11-15.80) 0.823 
 2006-2009 171 (61.7) 154 4 (57.1) 2.60 (0.71-6.65) 1.38 (0.15-12.73) 0.774 1.61 (0.16-16.57) 0.687 
          
Treatment experienced No 260 (93.9) 375 6 (85.7) 1.60 (0.59-3.48) Ref  Ref  
Yes 17 (6.1) 35 1 (14.3) 2.86 (0.07-15.92) 1.99 (0.24-16.57) 0.524 2.77 (0.28-27.87) 0.387 
          
Opiate or Injection related 
hospital admission prior to 
being initiated onto therapy 
No 178 (64.3) 261 2 (28.6) 0.77 (0.09-2.77) Ref  Ref  
Yes 99 (35.7) 149 5 (71.4) 3.36 (1.09-7.83) 4.68 (0.91-24.14) 0.065 2.44 (0.41-14.37) 0.326 
          
Opiate or Injection related 
hospital admission during 
follow-up 
No 248 (89.8) 322 2 (28.6) 0.62 (0.08-2.24) Ref  Ref  
Yes 29 (10.5) 88 5 (71.4) 5.68 (1.84-13.26) 14.02 (2.69-73.21) 0.002 12.89 (2.18-76.04) 0.005 
*At start of therapy.  PWID=People who inject drugs, RNA=Ribonucleic acid, CI=confidence interval, Ref=Reference category. 
 
